0001801834false--12-31Q2

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
Report of Foreign Private Issuer
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
For the month of August 2023
 
Commission File Number: 001-39481
 
PainReform Ltd.
(Translation of registrant’s name into English)
 
65 Yigal Alon St., Tel Aviv 6744316
Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F       Form 40-F  
 
This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and the Company’s Registration Statements on Form F-3 (Registration No. 333-259318 and 333-254982).
 

On August 10, 2023, PainReform Ltd. (the “Company”) issued a press release announcing its financial results for the six months ended June 30, 2023. The Company is also publishing its unaudited condensed financial statements, as well as its operating and financial review as of June 30, 2023 and for the six months then ended. Attached hereto are the following exhibits.
 
99.1
Unaudited Condensed Financial Statements as of June 30, 2023
 
 
99.2
Operating and Financial Review as of June 30, 2023 and for the six months then ended
 
 
99.3
Press Release dated August 10, 2023
 

Exhibit Index
 
Exhibit No.
 
Description
 
 
 
 
 
 
 
 
 
 

 
SIGNATURES 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: August 10, 2023
PAINREFORM LTD.
 
 
 
 
 
By:
/s/ Ilan Hadar
 
 
 
Ilan Hadar
 
 
 
Chief Executive Officer